Clinical trials
Phase 2 Peripheral Arterial Disease trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
47 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2005 | 4 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 5 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 32 |
| Terminated | 6 |
| Unknown status | 4 |
| Recruiting | 3 |
| Withdrawn | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Northwestern University | 4 |
| AnGes USA, Inc. | 2 |
| Celularity Incorporated | 2 |
| Duke University | 2 |
| Emory University | 2 |
| Novartis Pharmaceuticals | 2 |
| University of California, San Francisco | 2 |
| AMAG Pharmaceuticals, Inc. | 1 |
| AstraZeneca | 1 |
| Bijan Najafi, PhD | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Peripheral Arterial Disease | 47 |
| Intermittent Claudication | 15 |
| Peripheral Vascular Diseases | 9 |
| Vascular Diseases | 6 |
| Chronic Limb-Threatening Ischemia | 5 |
| Arterial Occlusive Diseases | 3 |
| Cardiovascular Diseases | 3 |
| Diabetes Mellitus | 3 |
| Mobility Limitation | 3 |
| Atherosclerosis | 2 |
Trials
Showing 1 to 25 of 47. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.